BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

The German biotech now hopes to leverage its COVID-19 vaccine success to launch new products over the next five years.

BioNTech Delivers Blowout Q1 Results

Shares in BioNTech surged 8% in U.S. premarket trading on Monday, after the German biotech's first-quarter earnings revealed a windfall of revenue and profit amid the global push to vaccinate against COVID-19.

BioNTech shares soar 8% in premarket as COVID-19 vaccines help revenues smash estimates

Pfizer

The block said on Sunday it hasn't renewed orders for the AstraZeneca vaccine, but announced a deal to buy as many as 1.8 billion doses of the Pfizer and BioNTech shot.

EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer.

CureVac B.V

BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday's premarket session after the company announced a Chinese joint venture to make 1 billion COVID-19 vaccine doses. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases including COVID-19.

What's Up WIth BioNTech Stock And CureVac Stock Today?

Shares of BioNTech (NASDAQ:BNTX) rose 8.3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 2134.62% over the past year to $5.29, which beat the estimate of $3.72.

Recap: BioNTech Q1 Earnings

Shares in BioNTech surged 8% in premarket trading on Monday, after the German biotechnology group reported first-quarter earnings. Jointly with Pfizer , BioNTech co-developed the first COVID-19 vaccine to receive the green light from regulators following large-scale clinical trials.

BioNTech shares soar 8% as COVID-19 vaccines drive revenue surge

The stock price of BioNTech SE (NASDAQ: BNTX) increased by over 8% pre-market. This is why it happened.

BNTX Stock: Over 8% Increase Pre-Market Explanation

Conference call and webcast scheduled for May 10, 2021, at 8:00 a.m. ET (2:00 p.m. CET)

BioNTech Announces First Quarter 2021 Financial Results and Corporate Update

BioNTech SE (NASDAQ: BNTX) will set up its Southeast Asia headquarters in Singapore and build a manufacturing facility to produce its messenger RNA vaccines and other medicines to treat infectious diseases and cancer. The new site would produce hundreds of million doses of mRNA-based vaccines each year, depending on the specific vaccine.

BioNTech Stock Jumps As It Plans New mRNA Manufacturing Facility In Singapore By 2023

The new manufacturing site would be able to produce several hundred of million doses of mRNA-based vaccines per year, depending on the type, BioNTech said.

BioNTech to produce vaccines in Singapore, its new regional headquarters

BioNTech said on Monday it plans to set up a regional headquarters and build a new manufacturing site for its vaccines based on messanger RNA technology (mRNA) in Singapore, in the latest move to expand its production network.

BioNTech to build mRNA manufacturing site in Singapore

MAINZ, GERMANY, May 10, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech's growing pipeline of mRNA-based product candidates, as well as a rapid response production capability for south east Asia to address potential pandemic threats.

BioNTech to Establish Regional Headquarters for South East Asia and First mRNA Manufacturing Facility in Singapore

The German drugmaker has additional drugs in its pipeline beyond its coronavirus vaccine.

Is BioNTech More Than a One-Trick Pony?

Investors should be focused on long-term data.

6 Months Later, Pfizer and BioNTech's Vaccine Data Continues to Impress

'This will be one less arrow in the concern quiver.'

Pfizer-BioNTech want full FDA approval for their vaccine — will a ‘yes' improve vaccine hesitancy?

Pfizer's CEO said the waiver proposal "will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine.'

Pfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues

BioNTech and Pfizer announced a filing for full FDA approval of their COVID-19 vaccine.

Why BioNTech Stock Popped Today

Now that the U.S. is getting close to authorizing the first COVID-19 vaccine for younger teens, it will pave the way for immunizations to begin to reach a broader group of Americans at a time when the pace of vaccinations is slowing.

The U.S. prepares to begin giving COVID-19 shots to 12- to 15-year-olds as Pfizer's vaccine nears expanded authorization

Pfizer and BioNTech have submitted an application for full FDA approval of their COVID-19 vaccine.

What Would Full FDA Approval Mean for the Pfizer Vaccine?

Pfizer began applying for full approval on Friday, a process that could take months.

Full FDA Approval Of Pfizer's Covid Shot Could Make Vaccine Mandates More Likely

Pfizer and BioNTech are asking the Food and Drug Administration for full regulatory approval of their jointly-produced COVID-19 vaccine. The move would allow the companies to produce and distribute the shots even after the coronavirus pandemic state of emergency is lifted. Reports that the companies were seeking full approval first came Friday from CNN and CNBC.

Pfizer and BioNTech are filing for full approval of their COVID-19 vaccine with the FDA

Pfizer and BioNTech asked for full Food and Drug Administration approval of their Covid vaccine on Friday, leading BioNTech stock to pop. That followed patent questions that hurt shares.

Pfizer, BioNTech Seek Full FDA Approval For Covid Vaccine; Shares Pop

Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) have started the process to seek full approval from the U.S. Food and Drug Administration (FDA) for a COVID-19 vaccine. What Happened: The companies' vaccine was made accessible in the U.S. last December when the FDA issued an Emergency Use Authorization (EUA).

Pfizer And BioNTech Seek FDA's Full Approval For COVID-19 Vaccine

It's currently being administered in the US under an emergency use authorization.

Pfizer seeks full FDA approval of COVID-19 vaccine

Pfizer and BioNTech have begun submitting an application to the U.S. Food and Drug Administration for full approval of their Covid-19 vaccine.

News for BioNTech SE Stock (BNTX)